期刊
EUROPEAN JOURNAL OF CANCER PREVENTION
卷 20, 期 2, 页码 102-111出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CEJ.0b013e328341e38f
关键词
apoptosis; cervical cancer; specificity protein 1; tolfenamic acid
类别
资金
- Ministry of Education, Science and Technology [M10870050003-08N7005-00311, 2010-0007598]
- National Research Foundation of Korea [2010-0007598] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Earlier studies have shown that tolfenamic acid (Tol) exhibits anticancer activity in several cancer models by inhibiting tumor growth and angiogenesis. However, the chemopreventive effect of Tol on a cervical cancer model and the underlying mechanism of action are unknown. In this study, Tol was found to inhibit cell proliferation by inducing apoptosis without affecting cyclo-oxygenase 2 expression, but ampiroxicam did not. Tol decreases the specificity protein 1 (Sp1) mRNA and its promoter activity in KB cervical cancer cells, and the downregulation of Sp1 protein by affecting several proteins that contain GC-rich sites on their promoters. Studies using small interference RNA and an Sp1-specific inhibitor (mithramycin A) confirmed that the decrease in Sp1 by Tol affects survivin and p27. Tol also inhibited tumor growth and Sp1 protein in athymic nude mice xenografts. These results show that Tol could be a potent anticervical cancer drug that acts by regulating Sp1 protein and its downstream pathways. European Journal of Cancer Prevention 20: 102-111 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据